Cargando…
MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma
BACKGROUND: MYCN gene amplification is related to risk stratification. Therefore it is important to identify accurately the level of the MYCN gene as early as possible in neuroblastoma (NB); however, for patients with bone marrow (BM) metastasis who need chemotherapy before surgery, timely detection...
Autores principales: | Yue, Zhi-Xia, Huang, Cheng, Gao, Chao, Xing, Tian-Yu, Liu, Shu-Guang, Li, Xing-Jun, Zhao, Qian, Wang, Xi-Si, Zhao, Wen, Jin, Mei, Ma, Xiao-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374581/ https://www.ncbi.nlm.nih.gov/pubmed/28367105 http://dx.doi.org/10.1186/s12935-017-0412-z |
Ejemplares similares
-
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
por: Yue, Zhi-Xia, et al.
Publicado: (2019) -
MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma
por: Yue, Zhi‐Xia, et al.
Publicado: (2022) -
Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020) -
MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023) -
Bone Marrow Environment in Metastatic Neuroblastoma
por: Brignole, Chiara, et al.
Publicado: (2021)